CRISPR Therapeutics (NASDAQ:CRSP) had its price objective lifted by Chardan Capital from $25.00 to $72.50 in a report issued on Tuesday, MarketBeat reports. The brokerage currently has a buy rating on the stock.
Several other research firms have also recently commented on CRSP. TheStreet cut shares of CRISPR Therapeutics from a c rating to a d+ rating in a research report on Friday, May 11th. BidaskClub raised shares of CRISPR Therapeutics from a buy rating to a strong-buy rating in a research report on Monday. Zacks Investment Research raised shares of CRISPR Therapeutics from a sell rating to a hold rating in a research report on Tuesday, March 13th. Piper Jaffray reaffirmed an overweight rating and issued a $53.70 target price (down from $67.00) on shares of CRISPR Therapeutics in a research report on Friday, March 9th. Finally, SunTrust Banks reaffirmed a buy rating and issued a $65.00 target price on shares of CRISPR Therapeutics in a research report on Friday, March 9th. Four analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has an average rating of Buy and an average target price of $64.28.
Shares of CRSP opened at $64.04 on Tuesday. The firm has a market cap of $2.72 billion, a price-to-earnings ratio of -38.48 and a beta of 3.58. CRISPR Therapeutics has a twelve month low of $56.38 and a twelve month high of $59.00.
CRISPR Therapeutics (NASDAQ:CRSP) last announced its quarterly earnings results on Wednesday, May 9th. The company reported ($0.62) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.67) by $0.05. The business had revenue of $1.36 million during the quarter, compared to analysts’ expectations of $3.64 million. CRISPR Therapeutics had a negative net margin of 189.60% and a negative return on equity of 35.18%. The firm’s revenue for the quarter was down 49.6% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.54) EPS. equities research analysts expect that CRISPR Therapeutics will post -2.6 earnings per share for the current fiscal year.
In related news, Director Bradley J. Phd Bolzon sold 30,566 shares of the stock in a transaction dated Monday, April 30th. The shares were sold at an average price of $50.29, for a total value of $1,537,164.14. Following the completion of the transaction, the director now directly owns 43,986 shares in the company, valued at approximately $2,212,055.94. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Bradley J. Phd Bolzon sold 101,994 shares of the stock in a transaction dated Monday, April 23rd. The stock was sold at an average price of $50.68, for a total transaction of $5,169,055.92. Following the completion of the transaction, the director now owns 43,986 shares of the company’s stock, valued at $2,229,210.48. The disclosure for this sale can be found here. Over the last quarter, insiders sold 1,406,609 shares of company stock valued at $74,069,522. 37.70% of the stock is owned by company insiders.
Several institutional investors have recently modified their holdings of the stock. Versant Venture Management LLC bought a new position in shares of CRISPR Therapeutics in the 1st quarter worth about $210,551,000. NEA Management Company LLC increased its stake in shares of CRISPR Therapeutics by 8.2% in the 1st quarter. NEA Management Company LLC now owns 3,484,464 shares of the company’s stock worth $159,275,000 after acquiring an additional 263,736 shares in the last quarter. Farallon Capital Management LLC bought a new position in shares of CRISPR Therapeutics in the 4th quarter worth about $20,160,000. Franklin Resources Inc. increased its stake in shares of CRISPR Therapeutics by 8.9% in the 4th quarter. Franklin Resources Inc. now owns 794,533 shares of the company’s stock worth $18,656,000 after acquiring an additional 65,200 shares in the last quarter. Finally, Global Thematic Partners LLC increased its stake in shares of CRISPR Therapeutics by 11.2% in the 4th quarter. Global Thematic Partners LLC now owns 633,452 shares of the company’s stock worth $14,873,000 after acquiring an additional 63,611 shares in the last quarter. Institutional investors own 36.73% of the company’s stock.
CRISPR Therapeutics Company Profile
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, which targets sickle cell disease and beta-thalassemia with an ex vivo approach whereby cells are harvested from a patient, treated with a CRISPR/Cas9-based therapeutic and reintroduced into the patient.
Receive News & Ratings for CRISPR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CRISPR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.